Re Agreement

Provexis PLC
15 November 2007

For release at 07.00 16 November 2007


                                  PROVEXIS plc
                         ('Provexis' or the 'Company')

   EXCLUSIVE FRUITFLOW(R) TECHNOLOGY ASSESSMENT AGREEMENT WITH THE COCA-COLA
                                    COMPANY

Provexis plc (PXS.L), which discovers, develops and licenses
scientifically-proven functional food, medical food and dietary supplement
technologies, announces the signing of a 12 month exclusive technology
assessment agreement for its patented Fruitflow(R) anti-thrombotic technology
with The Coca-Cola Company.

The exclusivity agreement covers all beverages, with the exception of
mini-drinks. During the assessment period both parties will carry out a
programme of work including consumer testing, commercial assessment and
finalising regulatory approval in a range of territories. Subject to positive
results in these areas, the parties intend to proceed to a licensing agreement
during the period of exclusivity.

There are four sectors in which Provexis is seeking major partnerships, namely,
food and dairy, beverages, products for deep vein thrombosis, and dietary
supplements and medical products. The Company has an existing collaboration
agreement with Unilever for certain formats within the food and dairy sectors.

                                     -ends-

For further information please contact:

Stephen Moon, Chief Executive
Provexis plc                                                 Tel: [phone]

Tom Griffiths/Alasdair Younie                                Tel: [phone]
Arbuthnot Securities

Chris Steele
Adventis Financial PR                                        Tel: [phone]





                      This information is provided by RNS
            The company news service from the London Stock Exchange